Purchase this article with an account.
Ryohei Miyata, Kumiko Kato, Hisashi Matsubara, Maki Kozawa, Yoshitsugu Matsui, Masahiko Sugimoto, Mineo Kondo; Prognosis of eyes with supernormal flicker ERG amplitudes in eyes with CRVO. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4267. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We have reported that some eyes with central retinal vein occlusion (CRVO) have flicker ERGs amplitudes that are much larger than those of other eyes (Miyata et al. ARVO, 2016). These are called supernormal flicker ERGs. In this study, we investigated the prognosis of CRVO eyes with supernormal flicker ERG amplitudes.
Twenty-five eyes with unilateral CRVO in which the flicker ERGs were recorded from both eyes at the initial visit (16 men, 9 women; age, 71.2 years) were studied. RETeval was used to record flicker ERGs. Supernormal flicker ERGs were defined as those whose amplitudes were larger than 110% of that of the unaffected eye. All CRVO eyes were treated with intravitreal injections of ranibizumab (3+PRN regimen). The ischemic status with or without panretinal photocoagulation (PRP) and the best-corrected visual acuity (BCVA) were evaluated at 1 year.
Ten of 25 eyes (40%) had supernormal flicker ERGs at the initial visit (SN group). One of 10 eyes in the SN group (10%) converted from non-ischemic to ischemic CRVO and then underwent PRP. The other 9 eyes remained non-ischemic CRVO for a year. Seven of 15 eyes in the non-SN group (47%) were diagnosed with ischemic CRVO within a year and underwent PRP. At one year, the BCVA was 0.10 ± 0.19 logMAR units in the SN group and 0.90 ± 0.70 logMAR units in the non-SN group (P<0.01).
Supernormal flicker ERGs can be a sign of good prognosis for eyes with CRVO.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only